BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu X, He C, Zhu Y. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Front Microbiol 2022;13:998240. [DOI: 10.3389/fmicb.2022.998240] [Reference Citation Analysis]
2 Ho C, Liu T, Lin Y, Chen Y, Chen M, Wang H, Liou T. Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection. Microorganisms 2022;10:415. [DOI: 10.3390/microorganisms10020415] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Losurdo G, Lacavalla I, Russo F, Riezzo G, Brescia IV, Rendina M, Ierardi E, Di Leo A. Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. Antibiotics (Basel) 2022;11:78. [PMID: 35052955 DOI: 10.3390/antibiotics11010078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kim J, Gong EJ, Seo M, Seo HI, Park JK, Lee SJ, Han KH, Jeong WJ, Kim YD, Cheon GJ. Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection. JPM 2022;12:56. [DOI: 10.3390/jpm12010056] [Reference Citation Analysis]